Highest EBITDA
legend_toggleExplore a diverse array of industries, each represented by companies that have excelled in generating substantial EBITDA.
| name | PRICE | $ CHANGE | % CHANGE | MARKET CAP | VOLUME | AVG. VOLUME | arrow_downwardEBITDA | TECHNICALS | DIVIDEND Y | ROI 1Y | Score language | LAST 7 DAYS | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
APLSApellis Pharmaceuticals | $35.74 | -$1.87 | arrow_drop_down4.98% | $4.58B | 1.18M | 1.39M | -$311.30M | Neutralremove | - | -19.56% | AI Analysis | |||||
SWTXSpringWorks Therapeutics | $35.71 | -$1.71 | arrow_drop_down4.56% | $2.77B | 328.61K | 661.92K | -$318.70M | Neutralremove | - | 35.57% | AI Analysis | |||||
CHPTChargePoint Holdings | $1.37 | $0.00 | arrow_drop_up0.58% | $591.26M | 5.63M | 15.34M | -$318.96M | Neutralremove | - | -75.48% | AI Analysis | |||||
 IONSIonis Pharmaceuticals | $40.96 | -$1.23 | arrow_drop_down2.91% | $6.65B | 849.23K | 2.85M | -$330.67M | Neutralremove | - | -4.54% | AI Analysis | |||||
 PTONPeloton Interactive | $4.79 | $0.06 | arrow_drop_up1.26% | $1.78B | 4.86M | 12.81M | -$331.50M | Neutralremove | - | -4.96% | AI Analysis | |||||
 CRSPCRISPR Therapeutics AG | $48.01 | -$0.92 | arrow_drop_down1.89% | $4.16B | 541.82K | 884.47K | -$335.17M | Neutralremove | - | -5.07% | AI Analysis | |||||
IBRXImmunityBio | $3.50 | -$0.07 | arrow_drop_down2.09% | $2.49B | 1.12M | 2.72M | -$341.05M | Neutralremove | - | 94.72% | AI Analysis | |||||
BPMCBlueprint Medicines | $86.19 | -$2.71 | arrow_drop_down3.04% | $5.63B | 250.86K | 639.80K | -$343.12M | Neutralremove | - | 70.26% | AI Analysis | |||||
RXRXRecursion Pharmaceuticals | $6.57 | $0.00 | 0.00% | $1.85B | 1.62M | 4.59M | -$364.94M | Neutralremove | - | -23.33% | AI Analysis | |||||
ARVNArvinas | $25.40 | $0.35 | arrow_drop_up1.39% | $1.71B | 226.34K | 365.31K | -$366.20M | Neutralremove | - | 4.09% | AI Analysis | |||||
RLAYRelay Therapeutics | $8.19 | $0.59 | arrow_drop_up7.76% | $1.23B | 3.97M | 5.53M | -$367.86M | Neutralremove | - | -12.59% | AI Analysis | |||||
CFLTConfluent | $20.73 | $0.61 | arrow_drop_up3.03% | $6.49B | 1.66M | 2.80M | -$371.29M | Neutralremove | - | -35.58% | AI Analysis | |||||
WWayfair | $48.46 | $1.11 | arrow_drop_up2.35% | $5.84B | 2.22M | 4.19M | -$380.00M | Neutralremove | - | -31.73% | AI Analysis | |||||
 GHGuardant Health | $24.26 | -$2.52 | arrow_drop_down9.42% | $3.29B | 4.20M | 2.53M | -$382.20M | Neutralremove | - | -17.82% | AI Analysis | |||||
AGIOAgios Pharmaceuticals | $45.72 | -$0.96 | arrow_drop_down2.07% | $2.65B | 102.14K | 254.55K | -$399.09M | Neutralremove | - | 75.24% | AI Analysis | |||||
ACHRArcher Aviation | $3.11 | -$0.19 | arrow_drop_down6.03% | $1.17B | 11.41M | 10.85M | -$407.60M | Neutralremove | - | -51.78% | AI Analysis | |||||
 SPCEVirgin Galactic Holdings | $7.09 | $0.10 | arrow_drop_up1.43% | $199.10M | 1.28M | 1.04M | -$423.20M | Neutralremove | - | -82.70% | AI Analysis | |||||
SLRNACELYRIN, INC. - Common Stock | $4.22 | -$0.48 | arrow_drop_down10.21% | $469.09M | 593.79K | 657.01K | -$423.56M | Neutralremove | - | -62.91% | AI Analysis | |||||
 IOVAIovance Biotherapeutics | $10.03 | -$0.30 | arrow_drop_down2.94% | $3.13B | 3.07M | 6.33M | -$439.25M | Neutralremove | - | 90.41% | AI Analysis | |||||
SAGESage Therapeutics | $7.57 | -$0.25 | arrow_drop_down3.25% | $478.02M | 199.40K | 623.88K | -$448.12M | Neutralremove | - | -63.96% | AI Analysis |
Showing 4921-4940 of 4977
Results per page:
About Highest EBITDA
Discover the stocks with the highest EBITDA, a significant financial metric indicating a company's operational profitability. EBITDA, or earnings before interest, taxes, depreciation, and amortization, reflects a firm's ability to generate profits from its core operations without factoring in financing and accounting decisions.
Investors seek companies with robust EBITDA figures as it showcases their potential for sustainable growth and cash flow generation. High EBITDA stocks often demonstrate strong financial health and efficiency, making them attractive choices for long-term investment strategies.
Discover the Power of Stocklytics Tools
Our suite of tools empowers you to make informed decisions, seize opportunities, and stay ahead in the competitive trading world.
See Stocklytics Tools